TRANXENE Drug Patent Profile
✉ Email this page to a colleague
When do Tranxene patents expire, and when can generic versions of Tranxene launch?
Tranxene is a drug marketed by Ajenat Pharms and is included in one NDA.
The generic ingredient in TRANXENE is clorazepate dipotassium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clorazepate dipotassium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tranxene
A generic version of TRANXENE was approved as clorazepate dipotassium by AUROBINDO PHARMA on July 17th, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRANXENE?
- What are the global sales for TRANXENE?
- What is Average Wholesale Price for TRANXENE?
Summary for TRANXENE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| Clinical Trials: | 3 |
| Patent Applications: | 339 |
| Drug Prices: | Drug price information for TRANXENE |
| What excipients (inactive ingredients) are in TRANXENE? | TRANXENE excipients list |
| DailyMed Link: | TRANXENE at DailyMed |
Recent Clinical Trials for TRANXENE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Polish Lymphoma Research Group | Phase 4 |
| Ranbaxy Laboratories Limited | N/A |
US Patents and Regulatory Information for TRANXENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | CAPSULE;ORAL | 017105-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ajenat Pharms | TRANXENE SD | clorazepate dipotassium | TABLET;ORAL | 017105-005 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | TABLET;ORAL | 017105-006 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ajenat Pharms | TRANXENE SD | clorazepate dipotassium | TABLET;ORAL | 017105-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | CAPSULE;ORAL | 017105-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRANXENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | CAPSULE;ORAL | 017105-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | TABLET;ORAL | 017105-006 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | TABLET;ORAL | 017105-007 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | TABLET;ORAL | 017105-008 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | CAPSULE;ORAL | 017105-003 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRANXENE
See the table below for patents covering TRANXENE around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
